Lazaro Hiram Betancourt

This study integrates histopathology and proteogenomic data from melanoma metastases to identify subtypes and risk factors, offering a basis for personalized treatment strategies.

This paper identifies potential drug targets and predicts treatment efficacy and resistance in melanoma subtypes using proteogenomic data and drug sensitivity analysis.

The paper identifies six proteins that predict response to immune checkpoint therapy across three melanoma cohorts and correlate with patient survival.